Inovio Pharmaceuticals (NASDAQ: INO) isn't a particularly well-known or prominent name in the biotech industry, but some may remember it as one of those smaller companies that sought to develop and ...

This was the stock's second consecutive day of losses.

What are the allegations? Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device According to the complaint, ...

Inovio Pharmaceuticals remains a high-risk, event-driven play, with the investment case dominated by the binary FDA decision ...

Inovio Pharmaceuticals Inc (NASDAQ:INO) shares are trading lower by 40% to $2.23 during Friday’s session after the company priced a public offering of 10 million shares of common stock and ...

Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash ...

Inovio Pharmaceuticals (INO) shares soared 6.8% in the last trading session to close at $5.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Inovio Pharmaceuticals' innovative DNA platform could soon lead to an approval. However, the company still faces serious obstacles in the near and medium term. 10 stocks we like better than Inovio ...